YuriMaricichMDMBA

Summary

• Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist. He works to improve our healthcare system by investing in, advising for, & providing leadership at innovative firms. He has worked with & lead successful teams and programs at healthcare & life science/biotech (HLS) firms including Xdynia (acquired by Cavion), Corixa (acquired by GlaxoSmithKline), Pear Therapeutics (1st FDA-cleared, clinically-validated digital therapeutic to treat disease) and maintains patient care practice. He founded a digital health firm as a 3rd year med student that structured clinical data using NLP.
  
  He has worked with HLS, biotech and investment firms, including therapeutics, a leading cloud computing firm, digital health, healthcare, device, and IP law. He invests in public and private firms and has directly raised millions of institutional financing.
  
  Focus/interest includes biotechnology, therapeutics, diagnostics, genomics, delivery, AI/analytics, digital health, value-driven care, services & mobile health. Dr. Maricich was in Michael Porter’s first Value-Driven Health Care course at Harvard. As a 2nd year medical student he founded the Pathos Project. He is a published author & frequent speaker.
  
Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, his M.B.A. from Harvard Business School, and his undergraduate at the University of Notre Dame. He completed internal medicine training at the University of Virginia Health System.
  
  1) Physician, board-certified in Internal Medicine
  2) Chief Medical Officer & Head of Clinical Dev at Pear Therapeutics: leads the Clinical/Regulatory team, including leading reSET's clinical program & regulatory clearance: the first FDA-cleared prescription digital therapeutic to treat disease & reSET-O
  3) Investor: Asclepius Capital
  4) Consultant to biotech, therapeutic, digital investment, and IP law firms
  5) Founder, Pathos Project, a non-profit research instit